Skip to main content
Premium Trial:

Request an Annual Quote

Seahorse Bioscience Raises $5M in Private Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seahorse Bioscience yesterday said that it has raised $5 million in a Series D private financing.

The North Billerica, Mass.-based maker of cell analysis instruments said that it would use proceeds form the offering to expand its domestic and international sales and marketing efforts for its XF series analyzers for measuring cell metabolism.

Seahorse CEO Jay Teich called the financing "a milestone" for the firm. "We will use the funds to double our worldwide sales coverage and will be hiring at our manufacturing plant in Chicopee, [Mass.], ensuring that we keep pace with market demand for our XF system," he said in a statement.

Investors in this round included Commonwealth Capital Ventures, FLIR Systems Inc, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.